Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Inventory (2021 - 2025)

Historic Inventory for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $155.0 million.

  • Indivior Pharmaceuticals' Inventory fell 1292.13% to $155.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.0 million, marking a year-over-year decrease of 1292.13%. This contributed to the annual value of $167.0 million for FY2024, which is 3253.97% up from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Inventory is $155.0 million, which was down 1292.13% from $149.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' Inventory's 5-year high stood at $178.0 million during Q3 2024, with a 5-year trough of $95.0 million in Q4 2021.
  • Over the past 5 years, Indivior Pharmaceuticals' median Inventory value was $152.0 million (recorded in 2025), while the average stood at $146.2 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Inventory surged by 3253.97% in 2024 and then plummeted by 1292.13% in 2025.
  • Indivior Pharmaceuticals' Inventory (Quarter) stood at $95.0 million in 2021, then grew by 20.0% to $114.0 million in 2022, then grew by 10.53% to $126.0 million in 2023, then soared by 32.54% to $167.0 million in 2024, then dropped by 7.19% to $155.0 million in 2025.
  • Its last three reported values are $155.0 million in Q3 2025, $149.0 million for Q2 2025, and $163.0 million during Q1 2025.